WINT - Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions
- Windtree Therapeutics has an interesting portfolio in the underserved cardiovascular and pulmonary diseases.
- The company has favorable results in early trials.
- Although the stock is trading near 52-week lows, such small companies are inherently risky.
For further details see:
Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions